News

Academy of Immunohistochemistry
Results - general module run 53

B-cell specific activator protein (BSAP, PAX5): 198 labs participated, 86% sufficient, 46% optimal. Many clones could give optimal results, best performance was seen with DAK-Pax5 (Dako/Agilent). In contrast, rmAb clone 34 (Ventana/Roche, Cell Marque) gave a very low proportion of optimal results due to a generally poor signal-to-noise ratio.

Chromogranin (CGA): 296 labs participated, 76% sufficient, 51% optimal. mAb clone LK2H10 gave superior performance, both as Conc (many companies) and RTU systems (760-2519, Ventana/Roche, and others). In contrast, mAb clone DAK-A3 as Conc (Dako/Agilent), and mAb clone 5H7, both as Conc (Leica) and RTU (PA0430/PA0515, Leica), gave unsatisfactory results.

E-Cadherin (ECAD): 298 labs participated, 89% sufficient, 65% optimal. The RTU assays based on mAb clone NCH-38 (IS/IR/GA059, Dako/Agilent) and mAb clone 36 (790-4497, Ventana/Roche) gave a high proportion of optimal results. In contrast, RTU assays based on rmAb clone EP700Y (760-4440, Ventana/Roche, and 246R-18, Cell Marque) revealed poor signal-to-noise ratios or false positive staining reactions hampering interpretation of the specific signal for ECAD.

Mismatch repair protein PMS2 (PMS2): 246 labs participated, 89% sufficient, 58% optimal. The highest proportion of sufficient staining results was seen with rmAb clone EP51 based Autostainer RTU system (Dako/Agilent) and the rmAb clone EPR3947 based Benchmark RTU system (Ventana/Roche). However, as for the latter it is noteworthy that 80 out of 83 labs (96%) modified the protocol significantly in order obtain a better staining reaction, in fact changing the RTU system to a lab developed system.

Octamer transcription factor-3/4 (OCT3/4): 189 labs participated, 94% sufficient, 83% optimal. The Conc format of the mAbs clones MRQ-10 and N1NK provided a high proportion of optimal staining results on all the four main stainer platforms: Omnis (Dako/Agilent), Autostainer (Dako/Agilent), Bond (Leica) and BenchMark (Ventana/Roche). Also the mAb clone C-10 could provide optimal staining results on all four main stainer platforms, but the proportion of optimals were significantly lower on the BenchMark and Bond compared to the Omnis and Autostainer platforms.

Reassesment for run 53 will open together with run 54, B26, H14, C4 on 1st August.

July 2018
Mogens Vyberg
NordiQC director

Results - run 52, B25, H13 & C3

Run 52 (general module), B25 (breast cancer IHC module), H13 (HER2 ISH module) and C3 (Companion module) was accomplished December 2017 to April 2018. A very short summary of the results is given below. Click on the epitope name to see the complete general assessment results for each marker, including major causes of insufficient results, immunohistochemical critical assay performance controls (iCAPCs), and recommendable clones and protocols. Individual results are available after login on the homepage.

General module - run 52

Calretinin (CR): 269 labs participated, 72% sufficient, 45% optimal. Many clones may give optimal results.  Ready-to-Use (RTU) assays generally performed better than lab developed (LD) assays indicating a need for better calibration of the latter. RTU assays should only be used on the platform for which they are developed!

MSH6: 242 labs participated, 52% sufficient, 33% optimal. Rabbit monoclonal antibodies (rmAbs) generally performed well, while the mouse monoclonal antibodies (mAbs), clone 44 and PU29 consistently failed.

Synaptophysin (SYP): 308 labs participated, 75% sufficient, 33% optimal. The lowest proportion of acceptable results both as RTU and LD assays were seen with mAbs clone SY38 (1 out of 3 sufficient) and clone MRQ-40 (9 out of 61 optimal).

Terminal deoxynucleotidyl Transferase (TdT): 225 labs participated, 82% sufficient, 39% optimal. The mAb clone SEN28 and the rmAb clone EP266 were the most successful antibodies for TdT. Efficient HIER, preferable in an alkaline buffer in combination with a sensitive and specific 3-step polymer/multimer based detection system gave the highest proportion of optimal results. Polyclonal antibodies gave virtually no optimal results.

Vimentin (VIM): 308 labs participated, 74% sufficient, 43% optimal. The mAb clones V9 and 3B4 and rmAb clone SP20, HIER in an alkaline buffer, careful calibration of the primary Ab and application of a sensitive 3-step polymer/multimer based detection system were the most important parameters for an optimal performance. The clone V9 RTU assay from Roche/Ventana (790-2917) performed less well than V9 RTU assays from other companies.

Breast cancer IHC module - run B25

Estrogen receptor (ER): 361 labs participated, 92% sufficient, 57% optimal. Both LD and RTU assays generally perform well with the mAb clone 6F11 and rmAb clones SP1 and EP1. However, as for the Leica Bond mAb 6F11 RTU (PA009/PA0151) the lab modified protocols gave better results than the vendor recommended protocols.

HER2 IHC: 342 labs participated, 96% sufficient, 81% optimal. Despite an overall improvement of LD HER2 assays from run B1 to B25, the pass rate and proportion of optimal results is still inferior to the results of FDA/CE-IVD approved systems as PATHWAY® /CONFIRM™ and HercepTest™.

HER2 ISH module - run H13

HER2 ISH: 127 labs participated, 71% sufficient, 43% optimal. Optimal demonstration and evaluation of the HER2 gene amplification status could be obtained by all the applied dual-colour and one colour systems. For the most commonly used HER2 BRISH assay, the INFORM™ HER2 Dual ISH (Ventana/Roche), a technically adequate result was provided in 65% of the slides using appropriate and vendor recommended protocol settings. A similar issue has been observed consistently in the latest NordiQC HER2 BRISH assessments, indicating a challenge for the present assay to provide a reproducible performance. As this test is used by 79% of all participating laboratories applied with appropriate protocol settings, it significantly affects the pass rate. At present, no recommendations on how to improve the end result have been identified.

Companion module - run C3

PD-L1: 146 laboratories participated, a pass rate of 91% was observed. Both the three companion diagnostic PD-L1 IHC assays 28-8, SK005 Dako/Agilent, 22C3, SK006 Dako/Agilent and SP263, 790-4905 Ventana/Roche and the LD assays for PD-L1 provided a high pass rate. However, the assessment of C3 was challenged by less than optimal material circulated. It should be emphasized that the LD assays must be carefully validated before use for diagnostics.

April 20th 2018
Mogens Vyberg
Scheme director

Results - module 51, B24, H12, C2

Run 51 (general module), B24 (breast cancer IHC module), H12 (HER2 ISH module) and C2 (Companion module) was accomplished August to December 2017. A very short summary of the results is given below. Click on the epitope name to see the complete general assessment results for each marker, including major causes of insufficient results, immunohistochemical critical assay performance controls (iCAPCs), and recommendable clones and protocols. Individual results are available after login on the homepage.

General module 51

lu-ALK (lung anaplastic lymphoma kinase): 189 labs assessed, 61% sufficient, 38% optimal. The mAb clone OTI1A4 and the rmAb clone D5F3 were the most successful Abs for demonstration of EML4-ALK translocation in lung adenocarcinoma. For mAb clone 5A4 the analytical sensitivity was significantly lower. mAb ALK1 must not be used for lung adenocarcinoma. The Ventana clone D5F3 RTU system was the most successful assay with an overall pass rate of 100% when not modified by the laboratories. HIER at high pH and use of a sensitive 3-step polymer/multimer based detection system are crucial for an optimal performance.

AMACR (α-methylacyl-CoA racemase): 250 labs assessed, 93% sufficient, 55% optimal. The rmAb clones 13H4 and SP116, mAb clone EPMU1, and pAb p504S/CP200 were all robust Abs for demonstration of AMACR. Efficient HIER in an alkaline buffer and careful calibration of the primary Ab, in combination with a sensitive IHC system (3-step polymer/multimer system), were the main prerequisites for an optimal staining result.

CD30: 282 labs assessed, 83% sufficient, 50% optimal. The mAb clones Ber-H2, CON6D/5 and JCM182 could all be used to obtain optimal staining results. Efficient HIER in an alkaline buffer or modified low pH buffer, in combination with a sensitive and specific IHC system were the main prerequisites for optimal performance.

CD117: 277 labs assessed, 63% sufficient, 25% optimal. The rmAb clones YR145 and EP10 were the most successful both in a laboratory develop (LD) assay and in an RTU format, as the overall pass rate was 94% and the proportion of optimal results was 73%. Efficient HIER in an alkaline buffer, careful calibration of the primary Ab and use of a 3-step polymer/multimer detection system provided the highest proportion of optimal results. Assays based on the pAb A4502 (Dako) were used by the majority of participants, but only 53% were sufficient and 6% optimal. A similar pattern was seen with the RTU system based on the rmAb 9.7 (Ventana), where only 53% were sufficient and 3% optimal. Both Abs are difficult to calibrate to an acceptable level.

PAX8: 213 labs assessed, 56% sufficient, 20% optimal. Optimal staining results could be obtained with the mAbs clones BC12 and PAX8/1492, the pAb 10336-1-AP, 363A and CP379 and particularly the recently introduced rmAb clones EP298, SP348 and ZR-1. The most widely used PAX8 antibody, mAb clone MRQ-50, performed satisfactory on both the Leica Bond and Dako Autostainer platforms but had a very low pass rate on the Ventana BenchMark platform, both in a laboratory develop (LD) assay and in an RTU assay. The highest proportion of optimal results was obtained performing HIER in an alkaline buffer for at least 20 min. (32 min. for Ventana BenchMark) and use of a sensitive and specific 3-step polymer/multimer based detection system.

Breast cancer IHC module - run B24

ER: 386 labs participated, 92% sufficient, 71% optimal. Both lab developed and RTU assays generally perform well with the mAb clone 6F11 and rmAb clones SP1 and EP1. However, as for the RTUs the lab modified protocols generally gave better results than the vendor recommended protocols from Dako/Agilent, Leica and VMS/Roche: Grouped together, 163 out 203 (80%) of the lab modified RTU protocols gave optimal results, compared to 50 out of 74 (68%) of vendor recommended protocols. It is noteworthy that 203 out of 277 labs (73%) found need to modify the vendor recommended protocols in order to optimize the staining reaction.

HER2 IHC: 369 labs participated, 97% sufficient, 78% optimal. Despite an overall improvement of the pass rate for lab developed HER2 assays from run B1 to B24, the pass rate and proportion of optimal results is still inferior to the FDA/CE-IVD approved systems as PATHWAY® /CONFIRM™ and HercepTest™. In general, the three FDA-/CE-IVD approved HER2 assays provided a proportion of optimal results of 85% (226 of 266), whereas only 59% (61 of 103) of LD HER2 assays were assessed as optimal. On the other hand laboratory modified RTU assays seemed to perform better than the vendor recommended: Compiling the resuls of Agilent/Dako and Roche/VMS assays, 90 of 120 (75%) stains were optimal with the vendor recommended protocols, while 119 of 131 (91%) with the laboratory modify protocols. It is noteworthy that 146 out of 266 labs (55%) found need to modify the vendor recommended protocols in order to optimize the staining reaction.

PR: 385 labs participated, 99% sufficient, 77% optimal. Both lab developed assays and RTU assays generally perform well with the most widely used Abs clones 16, PgR 636, PgR 1294 and 1E2.

Breast cancer ISH module - run H12

HER2 ISH: 115 labs participated, 64% sufficient, 37% optimal. Technically optimal demonstration of HER2 BRISH could be obtained by the commercially available two-colour HER2 systems INFORM™ HER-2 Dual ISH (Ventana) and ZytoDot® 2C (ZytoVision), and the single-colour HER2 systems INFORM™ SISH system (Ventana) and ZytoDot® (ZytoVision). For all systems, retrieval settings – HIER and proteolysis – must be carefully balanced to provide sufficient demonstration of signals and preserve morphology. Despite optimal protocol settings, a high proportion of technically insufficient results were seen, which currently cannot be explained.

Companion module - run C2

PD-L1: 145 laboratories participated, a pass rate of 84% was observed. The three companion diagnostic PD-L1 IHC assays 28-8, SK005 Dako/Agilent, 22C3, SK006 Dako/Agilent and SP263, 790-4905 Ventana/Roche were most successful providing a pass rate of 95%. Laboratory developed (LD) assays for PD-L1 provided a pass rate of 73%, (in comparison, a pass rate of 20% in C1 for this group was observed). Access to best practice protocol settings for LD assays are being developed and published supporting the implementation of LD assays. However, it must be emphasized that the LD assays must be carefully validated before use for diagnostics.


December 15th 2017
Mogens Vyberg
Scheme director

QuIP/NordiQC Workshop Brugge 13-15 June '18

This 1st QuIP/NordiQC Workshop in Brugge, Belgium is aimed to give an update on basic and advanced immunohistochemical methods applied in diagnostic pathology, particularly for the classification of the unknown primary tumour as well as breast, lung and haematolymphoid tumours. The workshop will particularly focus on
- understanding the three phases in the technical test approach
- planning and diagnostic use of antibody panels
- optimization of staining protocols 
- use of recommended tissue controls 
- identification and handling of technical and diagnostic pitfalls
- image analysis of immunostains for diagnostic use

The target group comprises biomedical technicians and scientists or equivalent with some experience in immunohistochemistry, and residents and consultants in clinical and surgical pathology with special interest in the technical parts of immunohistochemistry. Maximum number of participants: 70. 

Programme and practical details

Click this link for registration NB! Fully booked, you may register for the waiting list

Results - module 50 available

Run 50 was accomplished January to July 2017. A very short summary of the results is given below. Click on the epitope name to see the complete general assessment results for each marker, including immunohistochemical critical assay performance controls (iCAPCs), recommendable clones and protocols, as well as major causes of insufficient results.
Individual results are sent to all participants by email.

Results general module - run 50

CD23: 270 labs assessed, 89% sufficient, 55% optimal. All stains deemed insufficient showed too weak reactions. Many clones provided optimal results. Irrespective of the clone, HIER in an alkaline buffer and careful calibration of the primary Ab in combination with a sensitive 3-step detection system are critical parameters for a sufficient result. On the Ventana BenchMark platform, rmAb SP23 should be preferred rather than mAb 1B12.     RTU systems for CD23 from the main IHC system providers were most successful.

CK19: 245 labs assessed, 82% sufficient, 42% optimal. HIER in an alkaline buffer, and careful calibration of the primary Ab in combination with a sensitive 3-step detection system are critical parameters for a sufficient result. Proteolytic pretreatment as single retrieval method is incompatible with an optimal result.

ERG: 130 labs assessed, 67% sufficient, 38% optimal. The prevalent feature of insufficient results was too weak or false negative staining reaction. HIER in an alkaline buffer, and careful calibration of the primary Ab in combination with a sensitive 3-step detection system are critical parameters for a sufficient result. Primary Ab selection is also important: mAb 9FY was less successful compared to rmAb clone EP111 and EPR3864. The Agilent/Dako RTU system based on rmAb clone EP111 provided the highest pass rate and proportion of optimal results.

MSH2: 231 labs assessed, 79% sufficient, 50% optimal. Most stains deemed insufficient showed too weak reactions but cases with false positive reactions or poor signal-to-noise ratio were also seen. The performance of mAb clone 25D12 was, as seen in previous asessments, inferior to mAb clones FE11 and G219-1129. mAb clone FE11 performs less well on the Ventana BenchMark platform, while with mAb G219-1129 no optimal results were seen with the Dako Autostainer and Leica Bond platforms. RTU systems for MSH2 from Agilent/Dako and Roche/Ventana were most successful.

S100: 299 labs assessed, 82% sufficient, 23% optimal. pAbs against S100 were most successful. HIER in an alkaline buffer and a careful calibration of the primary Ab are critical parameters for a sufficient result. Omission of HIER or use of proteolytic pre-treatment cannot be recommended. RTU systems based on pAbs from the main IHC providers gave relatively high pass rates, but few optimal results.

SMH: 109 labs assessed, 78% sufficient, 42% optimal. HIER in an alkaline buffer, and careful calibration of the primary Ab in combination with a sensitive 3-step detection system are critical parameters for a sufficient result. mAb clone SMMS-1 was the most widely used primary Ab and provided optimal results on all main IHC systems both within laboratory developed assays and RTU systems.

July 10th 2017
Mogens Vyberg, Scheme director

Results - module 49, B23, H11 & C1 available

Login to see individual results

CD5: 278 labs assessed, 92% sufficient, 68% optimal. Ready-To-Use (RTU) systems obtained superior pass rates and higher proportion of optimal results compared to laboratory developed (LD) tests. Within LD tests, optimal results required efficient HIER, preferable in alkaline buffer, and careful calibration of the primary Ab titre.

CK-LMW: 229 labs assessed, 80% sufficient, 31% optimal. The mAb clone cocktail B22.1/B23.1, rmAb clone cocktail EP17/30 and rmAb clone EP17 were the most successful antibodies for immunohistochemical demonstration of CK-LMW. In contrast mAb clone 34βH11 and in particular clones CAM5.2 are less successful and prevent improvement of the overall pass rate for CK-LMW.

MLA: 255 labs assessed, 60% sufficient, 32% optimal. The Ready-To-Use system for MLA from Dako (IR633/IS633 – AS48) based on mAb clone A103 applied according to the vendor recommended protocol settings provided the highest proportion of sufficient and optimal results. However, the clone showed less successful performance on the fully automated IHC platforms Omnis (Dako) and BenchMark (Ventana).

MLH1: 224 labs assessed, 59% sufficient, 30% optimal. Clone ES05 was most successful, both as concentrate and as RTU format (Dako/Agilent and Leica/Novocastra). The mAb clone M1 could not be used to obtain optimal staining for MHL1 due to aberrant nuclear staining in colon adenocarcinoma known to lack MLH1 expression.

NKX3.1: 49 labs assessed, 65% sufficient, 45% optimal. rmAb clone EP356 and pAb CP422 were the most successful antibodies. With LD assays, efficient HIER in an alkaline buffer and use of a sensitive and specific 3-step polymer/multimer based detection system gave the highest proportion of optimal results. Testis and normal prostate can be used as positive tissue controls

PSA: 284 labs assessed, 89% sufficient, 68% optimal. Careful calibration of the Ab concentration and sufficient HIER are required.

Results breast cancer IHC module - run B23

ER: 394 labs assessed, 92% sufficient, 56% optimal. The most used clones 6F11, EP1 and SP1 are all recommended.     RTU systems obtained superior pass rates and higher proportion of optimal results compared to LD assays. For LD assays, too low concentration of the Ab and insufficient HIER were major reasons for insufficient assays.

HER-2 IHC: 372 labs assessed, 95% sufficient, 82% optimal. The FDA-/CE-IVD approved PATHWAY®/CONFIRM™ (Ventana) and HercepTest™ (Dako) were the most precise assays for the semi-quantitative IHC determination of HER-2 protein expression. LD assays produced a lower pass-rate and were less precise for the HER-2 status requiring an additional ISH test for final evaluation. Inclusion of 2+ tumours with and without HER-2 gene amplification in the control material for both EQA and internal quality control is essential to evaluate precision and performance stability of the IHC HER-2 assays used by laboratories.

Results companion module - run C1

PD-L1: 68 labs assessed, 50% sufficient, 37% optimal. Suboptimal results are mostly related to unexplained technical issues, which prevent recommendations for improvement. The Dako/Agilent 22C3 pharmDx assay SK006, applied by protocol settings in compliance with the vendor recommendations, was most successful with an overall pass rate of 92%. LD assays were used by 44% of the labs and a pass rate of 20% was seen.

Results breast cancer ISH module - run H11

HER-2 ISH: 123 labs assessed (BRISH only), 60% sufficient, 32% optimal. Suboptimal results are mostly related to unexplained technical issues, which prevent recommendations for improvement. 

 

April 21st 2017

Mogens Vyberg

 

Scheme director 

Welcome to Aalborg
Results - module 48, B22, H10 available

Runs 48/B22/H10 were accomplished from September to December 2016. A very short summary of the technical test results is given below. Click on the epitope name to see the complete general assessment results for each marker, including recommended clones and protocols, as well as major causes of insufficient staining results, and for HER2 IHC/ISH and Ki67 also concordance of interpretation. Individual results are available for the participants by logging in.

Results general module - run 48

CDX2: 268 labs assessed, 80% sufficient, 58% optimal. Careful calibration of the Ab concentration and a sensitive visualization system are required. The old clones CDX-88 and AMT28 cannot be recommended. DAK-CDX2 should not be applied on the Ventana BenchMark platform.

Desmin (DES): 275 labs assessed, 87% sufficient, 48% optimal. Efficient Heat induced epitope retrieval (HIER) and a sensitive detection system are mandatory for an optimal result. Clone D33 should not be used on the Dako Omnis platform. RTU VMS mAb DE-R-11 (760-2513 for Ultra/XT) performed better with laboratory modified protocols than with the vendor recommended protocol (61% vs 0% optimal). In contrast RTU Dako mAb D33 (IR606/IS606 for AS48) performed better with the vendor recommended protocol than with laboratory modified protocols (80% vs 57% optimal).

MUM1: 211 labs assessed, 60% sufficient, 40% optimal. Efficient HIER, careful calibration of the Ab concentration and a sensitive visualization system are required for optimal performance. The clones rmAb MRQ-43, mAb MRQ-8 and mAb BC5 all produce insufficient results and cannot be recommended.

p40: 188 labs assessed, 74% sufficient, 42% optimal. Careful calibration of the Ab concentration and a sensitive visualization system are required. Polyclonal Abs cannot be recommended. RTU VMS mAb BC28 (790-4950 for Ultra/XT) performed better with laboratory modified protocols than with the vendor recommended protocol (57% vs 40% optimal).

p63: 274 labs assessed, 82% sufficient, 44% optimal. Efficient HIER, careful calibration of the Ab concentration and a sensitive visualization system are required for optimal performance. Clone 7JUL cannot be recommended, as almost all labs failed with this clone. RTU VMS mAb 4A4 (790-4509 for Ultra/XT) performed better with laboratory modified protocols than with the vendor recommended protocol (60% vs 20% optimal).

SOX10: 121 labs assessed, 68% sufficient, 50% optimal. Careful calibration of the Ab concentration and a sensitive visualization system are required. Polyclonal Abs cannot be recommended.

Results breast cancer IHC module - run B22

HER2 IHC: 387 labs assessed, 84% sufficient, 71% optimal. Pathway®/ConfirmTM (Ventana) and HercepTestTM (Dako) gave pass rates above 90% while the pass rates for OracleTM (Leica) and the laboratory developed kits were too low. Several labs are using approved systems off-label, which gives a lower pass rate and should be omitted, also for legal reasons. 

Ki67: 409 labs assessed, 93% sufficient, 69% optimal. Efficient HIER and careful calibration of the primary Ab concentration are mandatory. RTU systems gave a higher pass rates than laboratory developed protocols. MIB-1 showed an inferior performance on Bond, Leica.

Results breast cancer ISH module - run H10

HER2 ISH: 118 labs assessed (BRISH only), 68% sufficient, 32% optimal. Suboptimal results are mostly related to unexplained technical issues, which prevent recommendations for improvement. 

 

December 9th 2016

Mogens Vyberg

Scheme director 

 

Results general module - run 47

Runs 47 was accomplished April to July 2016. A very short summary of the tests is given below. Click on the epitope name to see the complete general assessment results for each marker, including recommended clones and protocols, and major causes of insufficient staining results. Individual results will be sent to participant by email.

Figure: Serial sections of GIST stained for CD117 in two labs. Left: optimal, right: false negative due to an insufficient protocol.

CD117: 272 participants, 47% sufficient, 14% optimal. Best results were obtained with rmAb clones YR145 and EP10, both as concentrates and in RTU formats, while pAb 4502 (Dako) gave less satisfactory results, and rmAb clone 9.7 (RTU 790-2951, Ventana) performed poorly. HIER in an alkaline buffer in combination with careful calibration of the primary Ab were the most critical parameters for a sufficient result. See photo above

CEA: 255 participants, 42% sufficient, 17% optimal. Best results were obtained with mAb clones CEA31 (both as concentrates and in RTU formats) and COL-1 (as concentrate). mAb clone II-7 gave less satisfactory results (particularly on the Ventana Benchmark platform), and mAb clone TF3H8-1 (RTU 760-2507, Ventana) performed poorly. Optimal results could only be obtained with use of HIER in an alkaline buffer. The tissue material was more challenging than in previous runs, but the causes of sufficient and insufficient results are basically the same.

CK20: 284 participants, 92% sufficient, 62% optimal. Efficient HIER is recommended, proteolytic pretreatment generally gives a lower pass rate.

CK-PAN: 275 participants, 72% achieved a sufficient mark, 48% optimal. For Ab cocktails containing AE1/AE3 HIER is mandatory. mAb MNF116 requires proteolytic pretreatment but the clone performs less well than AE1/AE3.

CyD1: 257 participants, 94% sufficient, 54% optimal. Both rmAb clones EP12 and SP4 can be recommended. However, SP4 performed less optimal on the Bond platform.

SOX11: 79 participants, 66% sufficient, 27% optimal. mAb clones MRQ-58 and SOX11-C1 can both be recommended. However, clone MRQ-58 in RTU format from Ventana (760-4888) works better with OptiView than UltraView (that is receommended by the producer).

Run 48, B22, H10 opens for protocol submission on 12th August.

July 11th 2016
Mogens Vyberg
Scheme director